Selected research
Industry Research
Lexapro Industry Research Report 2026
Market perspective
The global Lexapro market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Lexapro is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Lexapro is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Lexapro is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Lexapro include Zhejiang Conba Pharmaceutical (CN), Zhejiang Huahai Pharmaceutical (CN), Xidian Pharmaceutical (CN), Xian Janssen Pharmaceutical (CN), TEVA (Israel), Sichuan Kelun Pharmaceutical (CN), Jewim Pharmaceutical (Shandong), Novartis (US) and Mylan (US), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Lexapro market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Lexapro Market by Company
Zhejiang Conba Pharmaceutical (CN)
Zhejiang Huahai Pharmaceutical (CN)
Xidian Pharmaceutical (CN)
Xian Janssen Pharmaceutical (CN)
TEVA (Israel)
Sichuan Kelun Pharmaceutical (CN)
Jewim Pharmaceutical (Shandong)
Novartis (US)
Mylan (US)
Hunan Dongting Pharmaceutical (CN)
Lundbeck (DK)
Silarx Pharmacueticals (US)
Macleods Pharmaceuticals (IN)
Lupin (IN)
Hikma Pharmaceuticals (UK)
Hetero Drugs (IN)
Forest Laboratories (US)
Aurobindo Pharma (IN)
Apotex (CA)
Amneal Pharmaceuticals (US)
Accord Healthcare (IN)
Lexapro Segment by Type
Tablets
Solution
Lexapro Segment by Application
Children
Adults
Lexapro Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lexapro market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lexapro and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lexapro.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Lexapro manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Lexapro by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Lexapro in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Solution
Applications
- Children
- Adults
Companies covered
- Zhejiang Conba Pharmaceutical (CN)
- Zhejiang Huahai Pharmaceutical (CN)
- Xidian Pharmaceutical (CN)
- Xian Janssen Pharmaceutical (CN)
- TEVA (Israel)
- Sichuan Kelun Pharmaceutical (CN)
- Jewim Pharmaceutical (Shandong)
- Novartis (US)
- Mylan (US)
- Hunan Dongting Pharmaceutical (CN)
- Lundbeck (DK)
- Silarx Pharmacueticals (US)
- Macleods Pharmaceuticals (IN)
- Lupin (IN)
- Hikma Pharmaceuticals (UK)
- Hetero Drugs (IN)
- Forest Laboratories (US)
- Aurobindo Pharma (IN)
- Apotex (CA)
- Amneal Pharmaceuticals (US)
- Accord Healthcare (IN)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Lexapro Market Size (2021-2032)
- 2.2.2 Global Lexapro Sales (2021-2032)
- 2.2.3 Global Lexapro Market Average Price (2021-2032)
- 2.3 Lexapro by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablets
- 2.3.3 Solution
- 2.4 Lexapro by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Children
- 2.4.3 Adults
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Lexapro Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Lexapro Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Lexapro Revenue of Manufacturers (2021-2026)
- 3.4 Global Lexapro Average Price by Manufacturers (2021-2026)
- 3.5 Global Lexapro Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Lexapro, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Lexapro, Product Type & Application
- 3.8 Global Manufacturers of Lexapro, Established Date
- 3.9 Global Lexapro Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Zhejiang Conba Pharmaceutical (CN)
- 4.1.1 Zhejiang Conba Pharmaceutical (CN) Company Information
- 4.1.2 Zhejiang Conba Pharmaceutical (CN) Business Overview
- 4.1.3 Zhejiang Conba Pharmaceutical (CN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Zhejiang Conba Pharmaceutical (CN) Lexapro Product Portfolio
- 4.1.5 Zhejiang Conba Pharmaceutical (CN) Recent Developments
- 4.2 Zhejiang Huahai Pharmaceutical (CN)
- 4.2.1 Zhejiang Huahai Pharmaceutical (CN) Company Information
- 4.2.2 Zhejiang Huahai Pharmaceutical (CN) Business Overview
- 4.2.3 Zhejiang Huahai Pharmaceutical (CN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Zhejiang Huahai Pharmaceutical (CN) Lexapro Product Portfolio
- 4.2.5 Zhejiang Huahai Pharmaceutical (CN) Recent Developments
- 4.3 Xidian Pharmaceutical (CN)
- 4.3.1 Xidian Pharmaceutical (CN) Company Information
- 4.3.2 Xidian Pharmaceutical (CN) Business Overview
- 4.3.3 Xidian Pharmaceutical (CN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Xidian Pharmaceutical (CN) Lexapro Product Portfolio
- 4.3.5 Xidian Pharmaceutical (CN) Recent Developments
- 4.4 Xian Janssen Pharmaceutical (CN)
- 4.4.1 Xian Janssen Pharmaceutical (CN) Company Information
- 4.4.2 Xian Janssen Pharmaceutical (CN) Business Overview
- 4.4.3 Xian Janssen Pharmaceutical (CN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Xian Janssen Pharmaceutical (CN) Lexapro Product Portfolio
- 4.4.5 Xian Janssen Pharmaceutical (CN) Recent Developments
- 4.5 TEVA (Israel)
- 4.5.1 TEVA (Israel) Company Information
- 4.5.2 TEVA (Israel) Business Overview
- 4.5.3 TEVA (Israel) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 TEVA (Israel) Lexapro Product Portfolio
- 4.5.5 TEVA (Israel) Recent Developments
- 4.6 Sichuan Kelun Pharmaceutical (CN)
- 4.6.1 Sichuan Kelun Pharmaceutical (CN) Company Information
- 4.6.2 Sichuan Kelun Pharmaceutical (CN) Business Overview
- 4.6.3 Sichuan Kelun Pharmaceutical (CN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sichuan Kelun Pharmaceutical (CN) Lexapro Product Portfolio
- 4.6.5 Sichuan Kelun Pharmaceutical (CN) Recent Developments
- 4.7 Jewim Pharmaceutical (Shandong)
- 4.7.1 Jewim Pharmaceutical (Shandong) Company Information
- 4.7.2 Jewim Pharmaceutical (Shandong) Business Overview
- 4.7.3 Jewim Pharmaceutical (Shandong) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Jewim Pharmaceutical (Shandong) Lexapro Product Portfolio
- 4.7.5 Jewim Pharmaceutical (Shandong) Recent Developments
- 4.8 Novartis (US)
- 4.8.1 Novartis (US) Company Information
- 4.8.2 Novartis (US) Business Overview
- 4.8.3 Novartis (US) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Novartis (US) Lexapro Product Portfolio
- 4.8.5 Novartis (US) Recent Developments
- 4.9 Mylan (US)
- 4.9.1 Mylan (US) Company Information
- 4.9.2 Mylan (US) Business Overview
- 4.9.3 Mylan (US) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Mylan (US) Lexapro Product Portfolio
- 4.9.5 Mylan (US) Recent Developments
- 4.10 Hunan Dongting Pharmaceutical (CN)
- 4.10.1 Hunan Dongting Pharmaceutical (CN) Company Information
- 4.10.2 Hunan Dongting Pharmaceutical (CN) Business Overview
- 4.10.3 Hunan Dongting Pharmaceutical (CN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Hunan Dongting Pharmaceutical (CN) Lexapro Product Portfolio
- 4.10.5 Hunan Dongting Pharmaceutical (CN) Recent Developments
- 4.11 Lundbeck (DK)
- 4.11.1 Lundbeck (DK) Company Information
- 4.11.2 Lundbeck (DK) Business Overview
- 4.11.3 Lundbeck (DK) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Lundbeck (DK) Lexapro Product Portfolio
- 4.11.5 Lundbeck (DK) Recent Developments
- 4.12 Silarx Pharmacueticals (US)
- 4.12.1 Silarx Pharmacueticals (US) Company Information
- 4.12.2 Silarx Pharmacueticals (US) Business Overview
- 4.12.3 Silarx Pharmacueticals (US) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Silarx Pharmacueticals (US) Lexapro Product Portfolio
- 4.12.5 Silarx Pharmacueticals (US) Recent Developments
- 4.13 Macleods Pharmaceuticals (IN)
- 4.13.1 Macleods Pharmaceuticals (IN) Company Information
- 4.13.2 Macleods Pharmaceuticals (IN) Business Overview
- 4.13.3 Macleods Pharmaceuticals (IN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Macleods Pharmaceuticals (IN) Lexapro Product Portfolio
- 4.13.5 Macleods Pharmaceuticals (IN) Recent Developments
- 4.14 Lupin (IN)
- 4.14.1 Lupin (IN) Company Information
- 4.14.2 Lupin (IN) Business Overview
- 4.14.3 Lupin (IN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Lupin (IN) Lexapro Product Portfolio
- 4.14.5 Lupin (IN) Recent Developments
- 4.15 Hikma Pharmaceuticals (UK)
- 4.15.1 Hikma Pharmaceuticals (UK) Company Information
- 4.15.2 Hikma Pharmaceuticals (UK) Business Overview
- 4.15.3 Hikma Pharmaceuticals (UK) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Hikma Pharmaceuticals (UK) Lexapro Product Portfolio
- 4.15.5 Hikma Pharmaceuticals (UK) Recent Developments
- 4.16 Hetero Drugs (IN)
- 4.16.1 Hetero Drugs (IN) Company Information
- 4.16.2 Hetero Drugs (IN) Business Overview
- 4.16.3 Hetero Drugs (IN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Hetero Drugs (IN) Lexapro Product Portfolio
- 4.16.5 Hetero Drugs (IN) Recent Developments
- 4.17 Forest Laboratories (US)
- 4.17.1 Forest Laboratories (US) Company Information
- 4.17.2 Forest Laboratories (US) Business Overview
- 4.17.3 Forest Laboratories (US) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.17.4 Forest Laboratories (US) Lexapro Product Portfolio
- 4.17.5 Forest Laboratories (US) Recent Developments
- 4.18 Aurobindo Pharma (IN)
- 4.18.1 Aurobindo Pharma (IN) Company Information
- 4.18.2 Aurobindo Pharma (IN) Business Overview
- 4.18.3 Aurobindo Pharma (IN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.18.4 Aurobindo Pharma (IN) Lexapro Product Portfolio
- 4.18.5 Aurobindo Pharma (IN) Recent Developments
- 4.19 Apotex (CA)
- 4.19.1 Apotex (CA) Company Information
- 4.19.2 Apotex (CA) Business Overview
- 4.19.3 Apotex (CA) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.19.4 Apotex (CA) Lexapro Product Portfolio
- 4.19.5 Apotex (CA) Recent Developments
- 4.20 Amneal Pharmaceuticals (US)
- 4.20.1 Amneal Pharmaceuticals (US) Company Information
- 4.20.2 Amneal Pharmaceuticals (US) Business Overview
- 4.20.3 Amneal Pharmaceuticals (US) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.20.4 Amneal Pharmaceuticals (US) Lexapro Product Portfolio
- 4.20.5 Amneal Pharmaceuticals (US) Recent Developments
- 4.21 Accord Healthcare (IN)
- 4.21.1 Accord Healthcare (IN) Company Information
- 4.21.2 Accord Healthcare (IN) Business Overview
- 4.21.3 Accord Healthcare (IN) Lexapro Sales, Revenue and Gross Margin (2021-2026)
- 4.21.4 Accord Healthcare (IN) Lexapro Product Portfolio
- 4.21.5 Accord Healthcare (IN) Recent Developments
5 Global Lexapro Market Scenario by Region
- 5.1 Global Lexapro Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Lexapro Sales by Region: 2021-2032
- 5.2.1 Global Lexapro Sales by Region: 2021-2026
- 5.2.2 Global Lexapro Sales by Region: 2027-2032
- 5.3 Global Lexapro Revenue by Region: 2021-2032
- 5.3.1 Global Lexapro Revenue by Region: 2021-2026
- 5.3.2 Global Lexapro Revenue by Region: 2027-2032
- 5.4 North America Lexapro Market Facts & Figures by Country
- 5.4.1 North America Lexapro Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Lexapro Sales by Country (2021-2032)
- 5.4.3 North America Lexapro Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Lexapro Market Facts & Figures by Country
- 5.5.1 Europe Lexapro Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Lexapro Sales by Country (2021-2032)
- 5.5.3 Europe Lexapro Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Lexapro Market Facts & Figures by Country
- 5.6.1 Asia Pacific Lexapro Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Lexapro Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Lexapro Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Lexapro Market Facts & Figures by Country
- 5.7.1 South America Lexapro Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Lexapro Sales by Country (2021-2032)
- 5.7.3 South America Lexapro Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Lexapro Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Lexapro Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Lexapro Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Lexapro Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Lexapro Sales by Type (2021-2032)
- 6.1.1 Global Lexapro Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Lexapro Sales Market Share by Type (2021-2032)
- 6.2 Global Lexapro Revenue by Type (2021-2032)
- 6.2.1 Global Lexapro Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Lexapro Revenue Market Share by Type (2021-2032)
- 6.3 Global Lexapro Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Lexapro Sales by Application (2021-2032)
- 7.1.1 Global Lexapro Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Lexapro Sales Market Share by Application (2021-2032)
- 7.2 Global Lexapro Revenue by Application (2021-2032)
- 7.2.1 Global Lexapro Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Lexapro Revenue Market Share by Application (2021-2032)
- 7.3 Global Lexapro Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Lexapro Value Chain Analysis
- 8.1.1 Lexapro Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Lexapro Production Mode & Process
- 8.2 Lexapro Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Lexapro Distributors
- 8.2.3 Lexapro Customers
9 Global Lexapro Analyzing Market Dynamics
- 9.1 Lexapro Industry Trends
- 9.2 Lexapro Industry Drivers
- 9.3 Lexapro Industry Opportunities and Challenges
- 9.4 Lexapro Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst